Special Issue

Breast Cancer: Biomarkers and Clinical Management

Message from the Guest Editors

In order to anticipate tumor detection, in very dense and young breasts, we are pleased to invite the scientific community and experts in this field to present their innovative research and studies in the following areas:

- Imaging: CEM (contrast enhancement mammography)
- Imaging: MRI (screening and ultrafast MRI and DWI) in young women
- New protocols and guidelines
- The application of AI algorithms for detection and biopsy guidance
- Advanced genetic screening techniques
- Clinical and genetic biomarkers
- Genomics and radiomics for the identification of therapeutic targets
- Analysis of the correlation between tumor occurrence and gut bacterial flora patterns
- Advances in anatomic pathology
- Personalized medicine for the treatment of breast cancer
- Advances in therapeutic lines (in situ Ca,B3)
- New surgical approaches
- New non-surgical approaches (cryoablation techniques, for example)
- New radiotherapy approaches
- New medical therapy approaches (chemotherapy and immunotherapy)

We welcome the cooperation of all researchers dedicated to advancing the field in question.

Guest Editors

Dr. Pierluigi Maria Rinaldi

Radiology Unit, Mater Olbia Hospital (Qatar Foundation Endowment and Policlinico Universitario Agostino Gemelli IRCCS Foundation), Strada Statale 125 Orientale Sarda, 07026 Olbia, Italy

Dr. Antonella Lai

Oncology Unit, Mater Olbia Hospital, Olbia, Italy

Dr. Rino Aldo Montella

Radiology Unit, Mater Olbia Hospital, Olbia, Italy



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/176597

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

